Nicholas Hoffman & Company LLC. Decreases Position in Colgate-Palmolive Company (CL)

Nicholas Hoffman & Company LLC. decreased its position in shares of Colgate-Palmolive Company (NYSE:CL) by 9.6% during the first quarter, according to its most recent filing with the SEC. The firm owned 21,802 shares of the company’s stock after selling 2,311 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Colgate-Palmolive were worth $1,596,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CL. Congress Asset Management Co. MA acquired a new position in shares of Colgate-Palmolive during the fourth quarter valued at about $48,550,000. Cigna Investments Inc. New acquired a new position in shares of Colgate-Palmolive during the fourth quarter valued at about $3,744,000. United Capital Financial Advisers LLC boosted its position in shares of Colgate-Palmolive by 3.3% in the fourth quarter. United Capital Financial Advisers LLC now owns 464,834 shares of the company’s stock valued at $30,419,000 after buying an additional 14,837 shares during the last quarter. Summit Global Investments acquired a new position in shares of Colgate-Palmolive during the fourth quarter valued at about $2,265,000. Finally, Shepherd Financial Partners LLC purchased a new stake in Colgate-Palmolive during the fourth quarter valued at approximately $269,000. Institutional investors and hedge funds own 73.69% of the company’s stock.

Colgate-Palmolive Company (CL) traded down 0.39% during midday trading on Friday, reaching $71.02. 3,317,565 shares of the company were exchanged. Colgate-Palmolive Company has a 52-week low of $63.43 and a 52-week high of $77.27. The company has a 50 day moving average of $72.30 and a 200-day moving average of $72.91. The company has a market capitalization of $62.56 billion, a price-to-earnings ratio of 26.39 and a beta of 0.80.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, July 21st. The company reported $0.72 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.72. Colgate-Palmolive had a return on equity of 3,121.95% and a net margin of 15.83%. The business had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.89 billion. During the same period in the previous year, the firm posted $0.70 EPS. The company’s quarterly revenue was down .5% on a year-over-year basis. On average, equities research analysts anticipate that Colgate-Palmolive Company will post $2.89 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 15th. Stockholders of record on Tuesday, July 18th were issued a dividend of $0.40 per share. The ex-dividend date was Friday, July 14th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.25%. Colgate-Palmolive’s dividend payout ratio is 59.48%.

Several analysts have commented on CL shares. Zacks Investment Research lowered shares of Colgate-Palmolive from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Jefferies Group LLC reissued a “hold” rating and set a $76.00 price target on shares of Colgate-Palmolive in a research report on Wednesday, May 17th. Bank of America Corporation increased their price objective on shares of Colgate-Palmolive from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. BidaskClub lowered shares of Colgate-Palmolive from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 12th. Finally, Vetr lowered shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and set a $76.67 price objective for the company. in a research report on Wednesday, May 17th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the company’s stock. Colgate-Palmolive currently has a consensus rating of “Hold” and a consensus price target of $75.82.

In other Colgate-Palmolive news, COO Justin Skala sold 74,374 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $72.51, for a total value of $5,392,858.74. Following the transaction, the chief operating officer now owns 97,177 shares in the company, valued at $7,046,304.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patricia Verduin sold 3,833 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $75.67, for a total value of $290,043.11. Following the completion of the transaction, the insider now owns 53,022 shares in the company, valued at approximately $4,012,174.74. The disclosure for this sale can be found here. Insiders have sold 221,802 shares of company stock worth $15,983,976 in the last quarter. 1.02% of the stock is currently owned by corporate insiders.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.